Advertisement

Update on Vaccination Clinical Trials for HPV-Related Disease

      Abstract

      Background

      Cervical cancer remains a major cause of cancer death in women worldwide. Moreover, human papillomavirus (HPV)-related disease of the urogenital tract (including preinvasive and invasive cervical, vaginal, vulvar, penile, and anal disease) remains a major cause of morbidity and mortality in the United States and internationally.

      Objective

      The goal of this article was to review the vaccines available as well as the major Phase III trials of the quadrivalent and bivalent vaccines for the prevention of HPV-related genital tract disease.

      Methods

      A literature search was performed through PubMed using the terms “HPV vaccination” and limited to clinical trials over the last 6 years. The most relevant and largest scale trials were included in this report.

      Results

      Prophylactic vaccination has emerged as an important tool that holds promise in decreasing the burden of HPV disease. However, HPV vaccination is known to be largely type-specific. Vaccination is most effective when administered at a younger age and before sexual activity and exposure to HPV. Large trials have been conducted and show efficacy of both the bivalent (HPV types 16 and 18) and quadrivalent (HPV types 6, 11, 16, and 18) vaccine in the prevention of preinvasive lesions and infection with these HPV types.

      Conclusions

      Future directions include development of more affordable vaccines with extended HPV-type coverage as well as implementation of feasible worldwide vaccination programs.

      Key words

      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Munoz N.
        • Castellsague X.
        • de Gonzalez A.B.
        • Gissmann L.
        Chapter 1: HPV in the etiology of human cancer.
        Vaccine. 2006; 24 (S3/1–10)
        • Hariri S.
        • Unger E.R.
        • Sternberg M.
        • et al.
        Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006.
        J Infect Dis. 2011; 204: 566-573
        • Dunne E.F.
        • Unger E.R.
        • Sternberg M.
        • et al.
        Prevalence of HPV infection among females in the United States.
        JAMA. 2007; 297: 813-819
        • Bernard H.U.
        • Burk R.D.
        • Chen Z.
        • et al.
        Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments.
        Virology. 2010; 401: 70-79
        • Bouvard V.
        • Baan R.
        • Straif K.
        • et al.
        A review of human carcinogens—part B: biological agents.
        Lancet Oncol. 2009; 10: 321-322
        • Garland S.M.
        • Hernandez-Avila M.
        • Wheeler C.M.
        • et al.
        Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
        N Engl J Med. 2007; 356: 1928-1943
        • Markowitz L..E
        • Dunne E.F.
        • Saraiya M.
        • et al.
        Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2007; 56: 1-24
        • Centers for Disease Control and Prevention (CDC)
        FDA licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP).
        MMWR Recomm Rep. 2010; 59: 626-629
        • Sanjose S.
        • Quint W.G.
        • Alemany L.
        • et al.
        Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
        Lancet Oncol. 2010; 11 (de): 1048-1056
        • Group F.I.
        Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
        N Engl J Med. 2007; 356: 1915-1927
        • Paavonen J.
        • Jenkins D.
        • Bosch F.X.
        • et al.
        Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
        Lancet. 2007; 369: 2161-2170
        • McCredie M.R.
        • Sharples K.J.
        • Paul C.
        • et al.
        Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.
        Lancet Oncol. 2008; 9: 425-434
        • Herrero R.
        • Hildesheim A.
        • Rodriguez A.C.
        • et al.
        Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
        Vaccine. 2008; 26: 4795-4808
        • Castellsague X.
        • Munoz N.
        • Pitisuttithum P.
        • et al.
        End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
        Br J Cancer. 2011; 105: 28-37
        • Lehtinen M.
        • Paavonen J.
        • Wheeler C.M.
        • et al.
        Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
        Lancet Oncol. 2012; 13: 89-99
        • Wheeler C.M.
        • Castellsague X.
        • Garland S.M.
        • et al.
        Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
        Lancet Oncol. 2012; 13: 100-110
        • Dobson S.R.
        • McNeil S.
        • Dionne M.
        • et al.
        Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
        JAMA. 2013; 309: 1793-1802
        • Kreimer A.R.
        • Rodriguez A.C.
        • Hildesheim A.
        • et al.
        Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
        J Natl Cancer Inst. 2011; 103: 1444-1451
        • Olsson S.E.
        • Villa L.L.
        • Costa R.L.
        • et al.
        Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
        Vaccine. 2007; 25: 4931-4939
        • Roteli-Martins C.M.
        • Naud P.
        • De Borba P.
        • et al.
        Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
        Human Vaccin Immunother. 2012; 8: 390-397
        • Rowhani-Rahbar A.
        • Alvarez F.B.
        • Bryan J.T.
        • et al.
        Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.
        J Clin Virol. 2012; 53: 239-243
        • Gee J.
        • Naleway A.
        • Shui I.
        • et al.
        Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
        Vaccine. 2011; 29: 8279-8284
        • Klein N.P.
        • Hansen J.
        • Chao C.
        • et al.
        Safety of quadrivalent human papillomavirus vaccine administered routinely to females.
        Arch Pediatr Adolesc Med. 2012; 166: 1140-1148
        • Kang L.W.
        • Crawford N.
        • Tang M.L.
        • et al.
        Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.
        BMJ. 2008; 337: a2642
        • Joura E.A.
        • Garland S.M.
        • Paavonen J.
        • et al.
        FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
        BMJ. 2012; 344: e1401
        • Dillner J.
        • Kjaer S.K.
        • Wheeler C.M.
        • et al.
        Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
        BMJ. 2010; 341: c3493
        • Kang W.D.
        • Choi H.S.
        • Kim S.M.
        Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?.
        Gynecol Oncol. 2013; 130: 264-268
        • Watson M.
        • Shaw D.
        • Molchanoff L.
        • McInnes C.
        Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
        Aust N Z J Public Health. 2009; 33: 365-370
        • Brabin L.
        • Roberts S.A.
        • Stretch R.
        • et al.
        Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study.
        BMJ. 2008; 336: 1056-1058
        • Widgren K.
        • Simonsen J.
        • Valentiner-Branth P.
        • Molbak K.
        Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark.
        Vaccine. 2011; 29: 9663-9667
        • Hayashi Y.
        • Shimizu Y.
        • Netsu S.
        • et al.
        High HPV vaccination uptake rates for adolescent girls after regional governmental funding in Shiki City, Japan.
        Vaccine. 2012; 30: 5547-5550
      1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.

        • Termrungruanglert W.
        • Havanond P.
        • Khemapech N.
        • et al.
        Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
        Value Health. 2012; 15: S29-S34
        • LaMontagne D.S.
        • Barge S.
        • Le N.T.
        • et al.
        Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.
        Bull World Health Organ. 2011; 89: 821B-830B
        • Smith J.S.
        • Lindsay L.
        • Hoots B.
        • et al.
        Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update.
        Int J Cancer. 2007; 121: 621-632
        • Van de Velde N.
        • Boily M.C.
        • Drolet M.
        • et al.
        Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
        J Natl Cancer Inst. 2012; 104: 1712-1723
        • Chen X.S.
        • Casini G.
        • Harrison S.C.
        • Garcea R.L.
        Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.
        J Mol Biol. 2001; 307: 173-182
        • Karanam B.
        • Jagu S.
        • Huh W.K.
        • Roden R.B.
        Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.
        Immunol Cell Biol. 2009; 87: 287-299